Impact of HIV-1 reverse transcriptase polymorphism F214L on virological response to thymidine analogue-based regimens in antiretroviral therapy (ART)-naive and ART-experienced patients

Journal of Infectious Diseases

Volumn 196, Issue 8, 2007, Pages 1180-1190

  Ceccherini Silberstein, Francesca ^a   Cozzi Lepri, Alessandro ^b   Ruiz, Lidia ^c   Mocroft, Amanda ^b   Phillips, Andrew N ^b   Olsen, Christian Holkmann ^e   Gatell, Jose M ^d   Günthard, Huldrych F ^f   Reiss, Peter ^g   Perno, Carlo Federico ^a   Clotet, Bonaventura ^c   Lundgren, Jens D ^e  

^a UNIVERSITY OF ROME TOR VERGATA   (Italy)

^b ROYAL FREE AND UNIVERSITY COLLEGE MEDICAL SCHOOL   (United Kingdom)

^c IrsiCaixa Foundation   (Spain)

^d UNIVERSITY OF BARCELONA   (Spain)

^e HVIDOVRE HOSPITAL   (Denmark)

^f UNIVERSITY HOSPITAL ZURICH   (Switzerland)

^g UNIVERSITY OF AMSTERDAM   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIRETROVIRUS AGENT; DIDANOSINE; INDINAVIR; LAMIVUDINE; NEVIRAPINE; PROTEINASE INHIBITOR; RITONAVIR; RNA DIRECTED DNA POLYMERASE; RNA DIRECTED DNA POLYMERASE INHIBITOR; STAVUDINE; THYMIDINE DERIVATIVE; ZIDOVUDINE;

ARTICLE; CONFIDENCE INTERVAL; DRUG MECHANISM; ENZYME POLYMORPHISM; GENOTYPE; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; MAJOR CLINICAL STUDY; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; PROPORTIONAL HAZARDS MODEL; VIRUS LOAD;

EUROPE; HIV INFECTIONS; HIV REVERSE TRANSCRIPTASE; HIV-1; HUMANS; MUTATION; POLYMORPHISM, SINGLE NUCLEOTIDE; RETROSPECTIVE STUDIES; REVERSE TRANSCRIPTASE INHIBITORS; THYMIDINE;

EID: 35348914691     PISSN: 00221899     EISSN: None     Source Type: Journal    
DOI: 10.1086/521678     Document Type: Article

References (40)

1. Clavel F, Hance AJ. HIV drug resistance. N Engl J Med 2004; 350: 1023-35.
2. Sarafianos SG, Das K, Clark AD Jr, et al. Touching the heart of HIV-1 drug resistance: the fingers close down on the dNTP at the polymerase active site. Chem Biol 1999; 6:R137-46.
3. Tantillo C, Ding J, Jacobo-Molina A, et al. Locations of anti-AIDS drug binding sites and resistance-mutations in the three-dimensional structure of HIV-1 reverse transcriptase: implications for mechanisms of drug inhibition and resistance. J Mol Biol 1994; 243:369-87.
4. Johnson VA, Brun-Vezinet F, Clotet B, et al. Update of the drug resistance mutations in HIV-1: fall 2006. Top HIV Med 2006; 14:125-30.
5. Stanford HIV Drug Resistance Database. Available at: http://hivdb. stanford.edu. Accessed 20 April 2007.
6. Meyer PR, Matsuura SE, So AG, Scott WA. Unblocking of chain-terminated primer by HIV-1 reverse transcriptase through a nucleotide-dependent mechanism. Proc Natl Acad Sci USA 1998; 95:13471-6.
7. Arion D, Kaushik N, McCormick S, Borkow G, Parniak MA. Phenotypic mechanism of HIV-1 resistance to 3′-azido-3′-deoxythymidine (AZT): increased polymerization processivity and enhanced sensitivity to pyrophosphate of the mutant viral reverse transcriptase. Biochemistry 1998; 37:15908-17.
8. Nikolenko GN, Palmer S, Maldarelli F, Mellors JW, Coffin JM, Pathak VK. Mechanism for nucleoside analog-mediated abrogation of HIV-1 replication: balance between RNase H activity and nucleotide excision. Proc Natl Acad Sci USA 2005; 102:2093-8.
9. Yahi N, Tamalet C, Tourres C, et al. Mutation patterns of the reverse transcriptase and protease genes in human immunodeficiency virus type 1-infected patients undergoing combination therapy: survey of 787 sequences. J Clin Microbiol 1999; 37:4099-106.
10. Jeeninga RE, Keulen W, Boucher C, Sanders RW, Berkhout B. Evolution of AZT resistance in HIV-1: the 41-70 intermediate that is not observed in vivo has a replication defect. Virology 2001; 283:294-305.
11. Hanna GJ, Johnson VA, Kuritzkes DR, et al. Patterns of resistance mutations selected by treatment of human immunodeficiency virus type 1 infection with zidovudine, didanosine, and nevirapine. J Infect Dis 2000; 181:904-11.
12. Gonzales MJ, Wu TD, Taylor J, et al. Extended spectrum of HIV-1 reverse transcriptase mutations in patients receiving multiple nucleoside analog inhibitors. AIDS 2003; 17:791-9.
13. Cozzi-Lepri A, Ruiz L, Loveday C, et al. Thymidine analogue mutation profiles: factors associated with acquiring specific profiles and their impact on the virological response to therapy. Antivir Ther 2005; 10: 791-802.
14. Marcelin AG, Delaugerre C, Wirden M, et al. Thymidine analogue reverse transcriptase inhibitors resistance mutations profiles and association to other nucleoside reverse transcriptase inhibitors resistance mutations observed in the context of virological failure. J Med Virol 2004; 72:162-5.
15. Rhee SY, Liu T, Ravela J, Gonzales MJ, Shafer RW. Distribution of human immunodeficiency virus type 1 protease and reverse transcriptase mutation patterns in 4,183 persons undergoing genotypic resistance testing. Antimicrob Agents Chemother 2004; 48:3122-6.
16. Miller MD, Margot N, Lu B, et al. Genotypic and phenotypic predictors of the magnitude of response to tenofovir disoproxil fumarate treatment in antiretroviral-experienced patients. J Infect Dis 2004; 189: 837-46.
17. Antinori A, Trotta MP, Nasta P, et al. Antiviral efficacy and genotypic resistance patterns of combination therapy with stavudine/tenofovir in highly active antiretroviral therapy experienced patients. Antivir Ther 2006; 11:233-43.
18. Tozzi V, Zaccarelli M, Narciso P, et al. Mutations in HIV-1 reverse transcriptase potentially associated with hypersusceptibility to nonnucleoside reverse-transcriptase inhibitors: effect on response to efavirenz-based therapy in an urban observational cohort. J Infect Dis 2004; 189:1688-95.
19. Ceccherini-Silberstein F, Gago F, Santoro M, et al. High sequence conservation of human immunodeficiency virus type 1 reverse transcriptase under drug pressure despite the continuous appearance of mutations. J Virol 2005; 79:10718-29.
20. Svicher V, Sing T, Santoro MM, et al. Involvement of novel HIV-1 reverse transcriptase mutations in the regulation of resistance nucleoside inhibitors. J Virol 2006; 80:7186-98.
21. Vandamme AM, Sonnerborg A, Ait-Khaled M, et al. Updated European recommendations for the clinical use of HIV drug resistance testing. Antivir Ther 2004; 9:829-48. Available at: http://www.kuleuven.ac.be/rega/cev/ pdf/vandammeAVT2004.pdf. Accessed 20 April 2007.
22. Whitcomb JM, Parkin NT, Chappey C, Hellman NS, Petropoulos CJ. Broad nucleoside reverse-transcriptase inhibitor crossresistance in human immunodeficiency virus type 1 clinical isolates. J Infect Dis 2003; 188:992-1000.
23. Ross L, Parkin N, Chappey C, et al. Phenotypic impact of HIV reverse transcriptase M184I/V mutations in combination with single thymidine analog mutations on nucleoside reverse transcriptase inhibitor resistance. AIDS 2004; 18:1691-6.
24. Quan H, Luo X, Capizzi T. Multiplicity adjustment for multiple end-points in clinical trials with multiple doses of an active treatment. Stat Med 2005; 24:2151-70.
25. Marschner IC, Betensky RA, DeGruttola V, Hammer SM, Kuritzkes DR. Clinical trials using HIV-1 RNA-based primary endpoints: statistical analysis and potential biases. J Acquir Immune Defic Syndr Hum Retrovirol 1999; 20:220-7.
26. Marcelin AG, Flandre P, Furco A, Wirden M, Molina JM, Calvez V. Impact of HIV-1 reverse transcriptase polymorphism at codons 211 and 228 on virological response to didanosine. AI454-176 Jaguar Study Team. Antivir Ther 2006; 11:693-9.
27. Sturmer M, Staszewski S, Doerr HW, Larder BA, Bloor S, Hertogs K. Correlation of phenotypic zidovudine resistance with mutational patterns in the reverse transcriptase of human immunodeficiency virus type 1: interpretation of established mutations and characterization of new polymorphisms at codons 208, 211, and 214. Antimicrob Agents Chemother 2003; 47:54-61.
28. Precious HM, Gunthard HF, Wong JK, et al. Multiple sites in HIV-1 reverse transcriptase associated with virological response to combination therapy. AIDS 2000; 14:31-6.
29. De Luca A, Di Giambenedetto S, Romano L, et al. Frequency and treatment-related predictors of thymidine-analogue mutation patterns in HIV-1 isolates after unsuccessful antiretroviral therapy. J Infect Dis 2006; 193:1219-22.
30. Lengauer T, Sing T. Bioinformatics-assisted anti-HIV therapy. Nat Rev Microbiol 2006; 4:790-7.
31. Sarafianos SG, Das K, Hughes SH, Arnold E. Taking aim at a moving target: designing drugs to inhibit drug-resistant HIV-1 reverse transcriptases. Curr Opin Struct Biol 2004; 14:716-30.
32. Shulman N, Bosch R, Fiscus S, Katzenstein D, Eron J. Mutations associated with didanosine resistance determined from 444 matched genotype-phenotype pairs. XIV International Drug Resistance Workshop: Basic Principles and Clinical Implications (Quebèc, Canada). Antivir Ther 2005; 10:S54.
33. Sing T, Svicher V, Beerenwinkel N, et al. Characterization of novel HIV drug resistance mutations using clustering, multidimensional scaling and SVM-based feature ranking. In: Jorge A, Torgo L, Brazdil P, Camacho R, Gama J, eds. Knowledge Discovery in Databases: PKDD. New York: Springer, 2005:285-96.
34. De Luca A, Perno CF, Ceccherini-Silberstein F, et al. Polymorphisms in the viral reverse transcriptase predict the evolution towards distinct thymidine analogue mutational patterns: a longitudinal analysis. ARCA Collaborative Group. XV International HIV Drug Resistance Work shop: Basic Principles and Clinical Implications (Sitges, Spain). Antivir Ther 2006; 11:S157.
35. Larder BA, Kemp SD. Multiple mutations in HIV-1 reverse transcriptase confer high-level resistance to zidovudine (AZT). Science 1989; 246:1155-8.
36. Boucher CAB, O'Sullivan E, Mulder JW, et al. Ordered appearance of zidovudine resistance mutations during treatment of 18 human immunodeficiency virus-positive subjects. J Infect Dis 1992; 165:105-10.
37. Marcelin AG, Flandre P, Pavie J, et al. Clinically relevant genotype interpretation of resistance to didanosine. Antimicrob Agents Chemother 2005; 49:1739-44.
38. Japour AJ, Welles S, D'Aquila RT, et al. Prevalence and clinical significance of zidovudine resistance mutations in human immunodeficiency virus isolated from patients following long-term zidovudine treatment. AIDS Clinical Trials Group 116B/117 Study Team and the Virology Committee Resistance Working Group. J Infect Dis 1995; 171:1172-9.
39. Kellam P, Boucher CAB, Larder BA. Fifth mutation in human immunodeficiency virus type 1 reverse transcriptase contributes to the development of high-level resistance to zidovudine. Proc Natl Acad Sci USA 1992; 89:1934-8.
40. DHHS Panel on Antiretroviral Guidelines for Adults and Adolescents. Guidelines for the use of antiretroviral agents in HIV-1-infected adults and adolescents. 10 October 2006. Available at: http://aidsinfo.nih.gov/.